Physician profile
David Grace
NPI 1740275577
$2,779.87
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $576 · 2021: $1,050 · 2022: $544 · 2023: $343 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.52 | 2020-2023 | Xifaxan |
| Abbvie INC. | $350.77 | 2021-2023 | |
| Pfizer INC. | $270.53 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $217.35 | 2020-2024 | Airsupra |
| Glaxosmithkline, LLC. | $201.41 | 2020-2023 | Shingrix |
| Exact Sciences Corporation | $177.80 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $157.30 | 2020-2023 | Repatha, Otezla |
| Novo Nordisk INC | $126.26 | 2019-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $121.86 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $95.88 | 2021 | |
| Biogen, INC. | $83.72 | 2020-2021 | |
| Allergan, INC. | $73.64 | 2020 | |
| Alphatec Spine, INC | $64.07 | 2020 | |
| Astellas Pharma US INC | $63.98 | 2019-2020 | |
| Lilly USA, LLC | $56.73 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $52.62 | 2022 | |
| Eisai INC. | $46.38 | 2020-2022 | |
| Boston Scientific Corporation | $43.46 | 2019-2023 | Watchman Access System |
| Radius Health, INC. | $38.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.26 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.02 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $32.26 | 2021 | |
| Abbott Laboratories | $20.19 | 2024 | Proclaim |
| Halozyme INC | $18.13 | 2023 | |
| Nevro Corp. | $17.88 | 2022 | |
| Insmed, INC. | $15.12 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Grace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.